416 related articles for article (PubMed ID: 30483124)
1. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
2. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.
Malinowski KP; Kawalec P; Trąbka W; Czech M; Petrova G; Manova M; Savova A; Draganić P; Vostalová L; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Front Pharmacol; 2019; 10():487. PubMed ID: 31139080
[TBL] [Abstract][Full Text] [Related]
3. Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries.
Stawowczyk E; Malinowski KP; Kawalec P; Bobiński R; Siwiec J; Panteli D; Eckhardt H; Simoens S; Agusti A; Dooms M; Pilc A
Front Pharmacol; 2019; 10():1279. PubMed ID: 31827433
[No Abstract] [Full Text] [Related]
4. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
[TBL] [Abstract][Full Text] [Related]
6. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.
Kwon HY; Kim H; Godman B
Front Pharmacol; 2018; 9():938. PubMed ID: 30233363
[No Abstract] [Full Text] [Related]
7. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
8. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
9. [Duration of the Reimbursement Process in Spain for Innovative Drugs Approved by the European Medicines Agency during the Period 2008-2013].
Pinyol C; Valmaseda A; Gómez-Ulloa D; Solozabal M; Restovic G
Rev Esp Salud Publica; 2015 Apr; 89(2):189-200. PubMed ID: 26121628
[TBL] [Abstract][Full Text] [Related]
10. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
11. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries.
Jakubowski S; Kawalec P; Holko P; Kowalska-Bobko I; Kamusheva M; Petrova G; Draganić P; Fuksa L; Männik A; Ispán F; Briedis V; Bianchi I; Paveliu MS; Tesar T
Front Pharmacol; 2024; 15():1369178. PubMed ID: 38523639
[No Abstract] [Full Text] [Related]
12. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
[TBL] [Abstract][Full Text] [Related]
13. ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; Gómez C; Gil A; Badia X
Orphanet J Rare Dis; 2023 Jan; 18(1):4. PubMed ID: 36609401
[TBL] [Abstract][Full Text] [Related]
14. NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances.
Pinilla-Dominguez P; Naci H; Osipenko L; Mossialos E
Int J Technol Assess Health Care; 2020 Jun; ():1-8. PubMed ID: 32638664
[TBL] [Abstract][Full Text] [Related]
15. The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs.
Vreman RA; Bloem LT; van Oirschot S; Hoekman J; van der Elst ME; Leufkens HG; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Int J Health Policy Manag; 2022 May; 11(5):642-650. PubMed ID: 33131224
[TBL] [Abstract][Full Text] [Related]
16. Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019.
Badia X; Vico T; Shepherd J; Gil A; Poveda-Andrés JL; Hernández C
Orphanet J Rare Dis; 2020 Aug; 15(1):224. PubMed ID: 32859228
[TBL] [Abstract][Full Text] [Related]
17. Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.
Brinkhuis F; Goettsch WG; Mantel-Teeuwisse AK; Bloem LT
BMJ; 2024 Feb; 384():e077391. PubMed ID: 38418086
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the evolution in the access to orphan medicines in Spain].
Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
[TBL] [Abstract][Full Text] [Related]
19. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
20. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
